![Multi-target FIT aims to offer inexpensive, high-sensitivity alternative to FIT in colorectal cancer screening](https://cdn.cancerletter.com/media/2024/03/01152633/50-09-4x3-1.jpg)
![Multi-target FIT aims to offer inexpensive, high-sensitivity alternative to FIT in colorectal cancer screening](https://cdn.cancerletter.com/media/2024/03/01152633/50-09-4x3-1.jpg)
Cover Story
Clinical
Developers of an investigational multi-target screening test for colorectal cancer and its precursors are aiming to replace the widely used conventional fecal immunochemical test.
Black History MonthFreeIn the Archives
By Robert A. Winn and Alexandria Carolan
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for March 2024
The National Cancer Institute approved the following clinical research studies last month. Â
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- Tweaking the existing systems is not the answer to drug shortages